{"schema_version":"secwatch.filing_event.v1","accession":"0001867096-23-000027","form_type":"8-K","ticker":"XERS","cik":"0001867096","company_name":"Xeris Biopharma Holdings, Inc.","filed_at":"2023-03-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.267335+00:00","generated_at":"2026-06-18T08:54:14.837148+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Xeris reports Q4 product revenue $32.5M (+52% YoY); guides 2023 revenue $135-165M, cash flow breakeven Q4 2023","bullets":["Q4 net product revenue $32.5M, up 52% YoY; full-year 2022 net product revenue $109.3M, up 38% pro forma.","Q4 net loss $12.9M ($0.10/sh); full-year net loss $94.7M ($0.70/sh). Cash at Dec 31, 2022: $122.0M.","2023 guidance: total revenue $135M-$165M, cash utilization $57-77M, year-end cash $45-65M; targets cash flow breakeven in Q4 2023.","Announced research collaboration with Horizon Therapeutics for XeriJect formulation of TEPEZZA; $2.75M upfront payment.","Gvoke NRx market share >28% at Feb 2023; Recorlev granted FDA orphan-drug exclusivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001867096-23-000027","json":"https://secwatch.observer/filing/0001867096-23-000027.json","markdown":"https://secwatch.observer/filing/0001867096-23-000027.md","text":"https://secwatch.observer/filing/0001867096-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/0001867096-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/xers-20230308.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T08:54:14.837148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21639ffb4656f3b51c6aa169e4a940f1c9812098","claim":"Xeris Biopharma Holdings, Inc. updated its the fourth quarter and full-year 2022 guidance (initiated).","evidence_excerpt":"Xeris Biopharma Holdings, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations and business highlights for the three and twelve months ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1867096/000186709623000027/0001867096-23-000027-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full-year 2022"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}